臨床外科74巻9号

2019年09月発行

特集 膵・消化管神経内分泌腫瘍—診断・治療の基本と最新動向

膵・消化管神経内分泌腫瘍の集学的治療

著者： 工藤篤¹ 赤星径一¹ 八木宏平¹ 石井武¹ 前川彩¹ 村瀬芳樹¹ 赤須雅文¹ 加藤智隆¹ 菅原俊喬¹ 渡辺秀一¹ 小倉俊郎¹ 小川康介¹ 小野宏晃¹ 伴大輔¹ 田中真二² 田邉稔¹

所属機関： ¹東京医科歯科大学肝胆膵外科学分野 ²東京医科歯科大学分子腫瘍学分野

ページ範囲：P.1092 - P.1096

【ポイント】
◆過去の報告によれば，神経内分泌腫瘍の同時性遠隔転移は膵臓，小腸，結腸の40〜45%，虫垂，胃，直腸の5〜15%に認められ，5年生存率は約30〜60%とされている．
◆2007年の本邦全国集計によれば，膵神経内分泌腫瘍は初診の約40%に同時性転移を認め，Stage Ⅳbの5年生存率は39%であった．当時は実質的な治療が手術しかなく，減量手術が全盛であった．
◆しかしながら，2011年以降に分子標的療法を含む新しい薬物が次々と保険適用になり，切除可能となる腫瘍が増加してきた．

参考文献

1）Yao JC, Hassan M, Phan A, et al：One hundred years after “carcinoid”：epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26：3063-3072, 2008

2）Frilling A, Modlin IM, Kidd M, et al：Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15：e8-e21, 2014

3）Kudo A, Akahoshi K, Ito S, et al：Downregulated pancreatic beta cell genes indicate poor prognosis in patients with pancreatic neuroendocrine neoplasms. Ann Surg, Jul 3, 2018［Epub ahead of print］

4）Mizuno Y, Kudo A, Akashi T, et al：Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 144：1155-1163, 2018

5）Shibuya H, Hijioka S, Sakamoto Y, et al：Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan：focus on weekly regimens and monotherapy. Cancer Chemother Pharmacol 82：661-668, 2018

6）Lamarca A, Elliott E, Barriuso J, et al：Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis：a lost cause? Cancer Treat Rev 44：26-41, 2016

Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 376：125-135, 2017

8）Modlin IM, Oberg K, Chung DC, et al：Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9：61-72, 2008

9）Dromain C, de Baere T, Lumbroso J, et al：Detection of liver metastases from endocrine tumors：a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23：70-78, 2005

10）Pavel M, Baudin E, Couvelard A, et al：ENETS Consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95：157-176, 2012

11）Mazzaferro V, Sposito C, Coppa J, et al：The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant 16：2892-2902, 2016

12）Sorbye H, Westre B, Horn A：Curative surgery after neoadjuvant chemotherapy in metastatic poorly differentiated neuroendocrine carcinoma. Eur J Surg Oncol 33：1209-1210, 2007

13）Prakash L, Bhosale P, Cloyd J, et al：Role of fluorouracil, doxorubicin, and streptozocin therapy in the preoperative treatment of localized pancreatic neuroendocrine tumors. J Gastrointest Surg 21：155-163, 2017

14）Ambe CM, Nguyen P, Centeno BA, et al：Multimodality management of “borderline resectable” pancreatic neuroendocrine tumors：report of a single-institution experience. Cancer Control 24：1073274817729076, 2017

15）Stoeltzing O, Loss M, Huber E, et al：Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 395：185-192, 2010

16）Ezziddin S, Lauschke H, Schaefers M, et al：Neoadjuvant downsizing by internal radiation：a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors. Clin Nucl Med 37：102-104, 2012

17）Claringbold PG, Brayshaw PA, Price RA, et al：Phase Ⅱ study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 38：302-311, 2011

18）Sato A, Masui T, Sankoda N, et al：A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor. Surg Case Rep 3：82, 2017

19）中沢祥子，三井哲弥，宮田陽一，他：Etoposide/Cisplatin（EP）療法施行後Conversion Surgeryが可能となった巨大膵神経内分泌癌の1切除例．癌と化療45：530-532, 2018

20）Haugvik SP, Janson ET, Osterlund P, et al：Surgical treatment as a principle for patients with high-grade pancreatic neuroendocrine carcinoma：a Nordic multicenter comparative study. Ann Surg Oncol 23：1721-1728, 2016

21）Galleberg RB, Knigge U, Tiensuu Janson E, et al：Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. Eur J Surg Oncol 43：1682-1689, 2017